Profile data is unavailable for this security.
About the company
Allergy Therapeutics plc is a United Kingdom-based international commercial biotechnology company. The Company is focused on the treatment and diagnosis of allergic disorders, including aluminum-free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine European countries and via distribution agreements in an additional ten countries. Its pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA, Bee Venom SCIT, Wasp Venom SCIT, Ragweed MATA MPL, Trees MATA, Trees MATA MPL, Peanut SCIT and others. Its commercial portfolio of products includes Pollinex, Venomil, Oralvac and Acarovac. It operates in Austria, Germany, Italy, the Netherlands, Spain, Switzerland, and the United Kingdom.
- Revenue in GBP (TTM)55.20m
- Net income in GBP-40.22m
- Incorporated2004
- Employees635.00
- LocationAllergy Therapeutics PLCDominion WayWORTHING BN14 8SAUnited KingdomGBR
- Phone+44 190 384 4700
- Fax+44 190 384 4726
- Websitehttps://www.allergytherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Futura Medical PLC | 8.40m | -3.75m | 101.06m | 12.00 | -- | 12.86 | -- | 12.03 | -0.0126 | -0.0126 | 0.0272 | 0.0259 | 0.8538 | 5,710.27 | 7.20 | 699,850.80 | -38.14 | -79.25 | -47.43 | -127.22 | 67.70 | -- | -44.68 | -914.37 | 3.75 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Scancell Holdings Plc | 0.00 | -5.86m | 139.44m | 61.00 | -- | -- | -- | -- | -0.0068 | -0.0068 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -23.24 | -31.66 | -32.48 | -37.66 | -- | -- | -- | -822.37 | -- | -- | 1.21 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
| hVIVO PLC | 64.38m | 17.45m | 150.36m | 274.00 | 8.76 | 3.91 | 7.28 | 2.34 | 0.0252 | 0.0252 | 0.0932 | 0.0565 | 0.9242 | -- | 4.25 | 234,974.50 | 25.04 | -0.643 | 46.68 | -1.29 | -- | -- | 27.10 | -0.765 | 1.60 | -- | 0.2530 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.34m | 153.95m | 34.00 | -- | 133.95 | -- | -- | -0.3166 | -0.3166 | 0.00 | 0.011 | 0.00 | -- | -- | 0.00 | -130.90 | -213.06 | -443.92 | -963.12 | -- | -- | -- | -- | -- | -5.99 | 0.9022 | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| Avacta Group Plc | 22.62m | -25.89m | 163.42m | 154.00 | -- | 3.32 | -- | 7.22 | -0.0867 | -0.0867 | 0.075 | 0.1334 | 0.2555 | 4.63 | 3.15 | 146,876.60 | -29.24 | -- | -61.16 | -- | 42.08 | -- | -114.45 | -- | 1.21 | -1.23 | 0.3875 | -- | 140.83 | -- | 32.54 | -- | -- | -- |
| 4Basebio PLC | 596.00k | -9.84m | 166.54m | -- | -- | -- | -- | 279.43 | -0.7843 | -0.7843 | 0.0476 | -0.4075 | 0.0508 | 0.6453 | 10.64 | -- | -83.78 | -- | -97.43 | -- | 69.63 | -- | -1,650.67 | -- | 2.53 | -18.44 | 1.51 | -- | 88.81 | -- | -48.83 | -- | -- | -- |
| Bioventix PLC | 13.61m | 8.10m | 195.74m | 17.00 | 24.53 | 16.31 | 23.84 | 14.39 | 1.53 | 1.53 | 2.57 | 2.30 | 1.01 | 1.57 | 2.26 | 800,387.60 | 59.95 | 58.33 | 67.24 | 63.62 | 93.20 | 93.09 | 59.51 | 64.12 | 7.07 | -- | 0.00 | 90.92 | 6.17 | 7.93 | -3.29 | 6.67 | -28.40 | 16.25 |
| Allergy Therapeutics plc | 55.20m | -40.22m | 262.15m | 635.00 | -- | 70.83 | -- | 4.75 | -0.0107 | -0.0107 | 0.0137 | 0.0008 | 0.8389 | 2.09 | 7.40 | -- | -61.12 | -22.88 | -86.97 | -30.15 | 53.87 | 66.47 | -72.86 | -24.88 | 1.01 | -8.70 | 0.8931 | -- | -7.36 | -5.62 | 6.63 | -- | 1.88 | -- |
| Puretech Health PLC | 369.96k | -65.19m | 388.36m | 90.00 | -- | 1.56 | -- | 1,049.74 | -0.2378 | -0.2378 | 0.0014 | 1.04 | 0.0007 | -- | 0.2252 | 4,110.65 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Oxford BioMedica plc | 97.28m | -142.02m | 436.93m | 834.00 | -- | 6.56 | -- | 4.49 | -1.44 | -1.44 | 0.9642 | 0.6292 | 0.3012 | 4.09 | 4.21 | 136,252.10 | -51.98 | -19.60 | -66.85 | -24.68 | 36.74 | 50.74 | -172.59 | -44.38 | 2.07 | -12.47 | 0.6077 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Genus plc | 668.80m | 7.90m | 1.11bn | 3.44k | 142.13 | 2.03 | 22.54 | 1.66 | 0.1186 | 0.1186 | 10.14 | 8.30 | 0.6569 | -- | 5.84 | 194,475.10 | 0.2357 | 3.30 | 0.2742 | 3.87 | -- | -- | 0.3589 | 4.98 | 1.21 | 93.17 | 0.3487 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
Data as of Nov 21 2024. Currency figures normalised to Allergy Therapeutics PLC's reporting currency: UK Pound GBX
3.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| JPMorgan Chase Bank, NA (Investment Management)as of 03 Sep 2024 | 124.00m | 2.60% |
| West Yorkshire Pension Fundas of 03 Sep 2024 | 13.88m | 0.29% |
| Hargreaves Lansdown Asset Management Ltd.as of 03 Sep 2024 | 12.25m | 0.26% |
| IG Markets Ltd.as of 03 Sep 2024 | 9.79m | 0.21% |
| HSBC Global Asset Management (UK) Ltd.as of 03 Sep 2024 | 4.70m | 0.10% |
| Santander Asset Management SA SGIICas of 03 Sep 2024 | 3.13m | 0.07% |
| Hauck Aufh�user Lampe Privatbank AGas of 03 Sep 2024 | 2.35m | 0.05% |
| Raiffeisen Kapitalanlage-Gesellschaft mbHas of 03 Sep 2024 | 2.12m | 0.05% |
| iDealing.com Ltd.as of 03 Sep 2024 | 1.42m | 0.03% |
| Bank Julius B�r & Co. AGas of 03 Sep 2024 | 1.39m | 0.03% |
More ▼
Data from 31 Mar 2024 - 05 Nov 2024Source: FactSet Research Systems Inc.
